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Abstract
Psoriasis is a chronic systemic, immune-mediated disorder of unknown aetiology,  usually 
presenting with typical inflammatory skin lesions and/or joint  manifestations, but sys-
temic inflammation that may lead to the development of co-morbidities may also be 
present. First-line therapy encompasses local cutaneous treatment and  phototherapy, but 
with more severe symptoms or systemic course, systemic treatment with  methotrexate 
(MTX), immunosuppressant cyclosporine, retinoid acitretin or  biologicals may be used. 
Treatment response varies between patients in terms of efficacy and/or toxicity, which 
could, among other reasons, be due to genetic differences between patients. Approximately 
10–30% of patients experience adverse drug reactions with MTX  treatment, leading to 
discontinuation of MTX mostly due to hepatotoxicity. Around 15% of patients experience 
adverse events when treated with biologicals; however, the most frequent reason for dis-
continuation is inefficacy or loss of the initially favourable response over time. Inefficacy 
or occurrence of adverse drug reactions cannot be predicted, so genetic biomarkers of 
drug response in combination with clinical data could be helpful in treatment planning. 
Several polymorphic genes have already been associated with treatment outcome, most 
of them involved in drug metabolism, transport and target pathways. Genetic biomark-
ers could be helpful in personalized care of psoriasis patients in order to prevent adverse 
events or predict inefficacy of a certain drug.
Keywords: psoriasis, pharmacogenetics, genetic polymorphisms, personalized 
medicine, methotrexate, biologic agents
1. Introduction
Psoriasis is a chronic systemic immune-mediated disorder of which etiopathogenesis is not 
yet fully understood, though there is evidence of genetic, immunologic and environmental 
factors playing a role in the development and the severity of the disease. The most common 
symptoms involve typical inflammatory skin lesions, but systemic inflammation may also be 
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present [1, 2]. Psoriatic arthritis (PsA) is the most frequent systemic manifestation that can 
accompany the skin lesions and occurs in up to 40% of patients [3]. Systemic inflammation is 
also one of the reasons for the occurrence of many other comorbidities in patients with pso-
riasis, such as metabolic syndrome which includes obesity, type 2 diabetes, hypertension and 
dyslipidaemia, cardiovascular diseases, chronic inflammatory bowel disease and also cancer 
in some cases [4]. Furthermore, lower quality of life and psychological disorders are also more 
frequent among psoriasis patients as compared to general population [5, 6]. It is proven that 
lifestyle, including diet, smoking and alcohol consumption, influences the occurrence and the 
course of psoriasis and the comorbidities [7]. Elevated body mass index and visceral fat can 
also increase the probability of more progressive course of the disease [7].
The severity of the disease is evaluated by the Psoriasis Area and Severity Index (PASI) score 
that takes into account the area of the affected skin, the thickness of skin plaques and the 
severity of inflammation. PASI score is calculated before the treatment strategy is chosen and 
is also used to monitor the treatment response. The response to treatment is considered to 
be good when PASI has decreased for at least 75% from the baseline score in 3–6 months 
after the first dose was administered (PASI75) [8]. The minimum treatment goal is usually 
set at PASI decreasing for at least 50% from the baseline score (PASI50). If PASI50 is not met, 
the treatment plan is usually changed [9]. However, PASI only evaluates the dermatological 
manifestations of the disease and neglects the psychological aspect. Therefore, Dermatology 
Life Quality Index (DLQI) is also assessed with a questionnaire to evaluate the impact of 
psoriasis on a patient’s physical, psychological and social well-being. The treatment goal is to 
achieve DLQI of zero to one after 2–4 months of treatment, but if this cannot be achieved, at 
least DLQI below five should be aimed for [9].
The patient’s response to systemic psoriasis treatment cannot be predicted. Furthermore, the 
interindividual variability in the treatment response is quite extensive and adverse events occur 
frequently [6]. A study conducted 3 years ago discovered that approximately 75% of traditional 
systemic drugs are discontinued after 143 days of treatment (p < 0.0001), mostly because of 
adverse events (p < 0.001) [8]. Besides the choice and the dose of the drug and patient’s compli-
ance to treatment, many other factors may influence the treatment response, such as patient’s 
demographic characteristics (age, gender, body mass, ethnicity), the severity of the disease, 
concomitant treatment with other drugs, patient’s diet, alcohol consumption, cigarette smok-
ing as well as comorbidities. However, a lot of attention has been lately focused on the role of 
genetic factors that may influence the course of the disease and treatment response [10, 11]. 
Several pharmacogenetics studies were performed to assess the influence of genetic factors 
on treatment response, mainly investigating the interindividual variability in genes involved 
in drug metabolism, transport and mechanisms of action and the association between genetic 
variability and the efficacy of treatment and the occurrence of adverse events [7, 12].
1.1. Genetic factors are associated with treatment response
Our genetic characteristics are encoded in our genome [13]. Interindividual differences between 
people are due to differences in less than 1% of genomic DNA sequence between unrelated 
individuals. Different variants of the same gene or genetic locus are called alleles. A variant is 
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called a polymorphism when there are at least two alleles present in the  population and the fre-
quency of the less prevalent allele is more than 1%. A great majority of variants are due to single 
nucleotide polymorphisms (SNPs), which means that alleles differ only in one nucleotide. In 
addition to SNPs, deletions, insertions, duplications of nucleotides or longer sequences, mic-
rosatellites, changes in variable number of tandem nucleotide repeats (VNTR) and others may 
account for genetic polymorphism. Genetic polymorphisms may influence the process of tran-
scription, translation and/or function of proteins. If variants change the binding site for differ-
ent regulatory proteins, transcription may be altered. Amino acids are encoded as a sequence of 
three nucleotides, called codons. If a polymorphism changes a codon, another amino acid can 
be incorporated into a protein, which can change the characteristics and function of a protein. 
Insertion of only one nucleotide causes frame shift, which results in a premature stop codon 
and non-functional protein. The same happens after a stop codon is formed in the middle of 
an exon or when SNPs alter mRNA splicing. Gene deletions may cause depletion of proteins 
while, on the other hand, gene duplications lead to excess of the encoded protein [14].
Genetic polymorphisms may also influence expression and function of proteins involved in 
drug metabolism and transport as well as drug targets and their effector pathways. Because 
of that, genetic polymorphisms may influence patients’ response to drugs and the occurrence 
of adverse effects. Pharmacogenetics studies the associations between genetic polymorphisms 
and the course of disease and response to treatment. The aim of this chapter is to summarize 
the current knowledge on pharmacogenetic polymorphisms that may influence the response 
to systemic treatment in patients diagnosed with psoriasis. Such polymorphisms have been 
investigated as predictive biomarkers of treatment response that would support personalized 
treatment approaches in patients with psoriasis.
2. Pharmacogenetics of systemic psoriasis treatment
2.1. Low-dose methotrexate
Methotrexate (MTX) is an immunomodulatory drug that is widely used in the treatment of 
psoriasis and PsA and is frequently the first-line systemic treatment for these two indications. 
It is usually orally administered once per week in doses of 7.5–30 mg [9]. Good response to 
treatment is achieved in approximately 50% of cases [8]. On the other hand, from 10 to 30% of 
patients have to discontinue the treatment because of adverse drug reactions. These include 
nausea, malaise, gastrointestinal ulcers, depression, infections, nephrotoxicity and most 
importantly hepatotoxicity and bone marrow suppression [9]. Adverse events are usually 
mild and can be eliminated by dose reduction. However, some adverse events may be severe 
or even life-threatening and cannot be predicted. This is the reason why patients treated with 
MTX are monitored very closely, and liver and kidney functions and blood status have to be 
checked regularly [8]. With the low doses used for psoriasis treatment, MTX plasma concen-
trations are too low to be measured, so drug monitoring cannot be used to predict the occur-
rence of adverse events. It has been therefore proposed that genetic polymorphisms should be 
investigated as predictors of response to treatment, either efficacy or toxicity [15–17].
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MTX is a folate analogue and as such inhibits folic acid metabolism. Folic acid is a donor of 
methyl group in the process of deoxythymidylate synthesis that is required for DNA syn-
thesis and cell proliferation as well as donor of methyl groups for methionine synthesis that 
directs the methyl group towards methylation reactions [18].
MTX enters the cell through the reduced folate carrier SLC19A1 and is activated by folylpoly- 
glutamate synthase that adds glutamate moieties to the molecule. MTX  polyglutamate pri-
marily inhibits dihydrofolate reductase (DHFR), thus inhibiting also thymidylate synthase 
(TYMS) reaction, which results in inhibition of DNA synthesis. Indirectly it inhibits also other 
enzymes of folate metabolic pathway and methylation  reactions, such as methylentetrahydro-
folate dehydrogenase (MTHFD1),  methylentetrahydrofolate reductase (MTHFR), methionine 
synthase (MS) and methionine-synthase reductase (MSR) (Figure 1) [19].
MTX is also adenosine pathway inhibitor. It inhibits the enzyme 5-aminoimidazole-4- car-
boxamide ribonucleotide (AICAR) transformylase (ATIC), which results in elevated levels of 
AICAR. AICAR inhibits adenosine deaminase (ADA) and this consequently leads to higher 
intercellular concentrations of adenosine. Adenosine is released into circulation, and its bind-
ing to adenosine receptors on the target cells contributes significantly to the anti-inflamma-
tory effects of MTX (Figure 1) [18].
Figure 1. Schematic view of MTX mechanism of action on folate and adenosine pathway. SLC19A1—reduced folate 
carrier, MTX—methotrexate, ABC—ABC transporters (ATP dependent), FPGS—folypolyglutamate synthase, GGH—
gamma-glutamyl hydrolase, MTXglu—methotrexate polyglutamate, DHFR—dihydrofolate reductase, THF—
tetrahydrofolate, MTHFD1—methylentetrahydrofolate dehydrogenase, SHMT1—serine hydroxymethyltransferase, 
MTHFR—methylentetrahydrofolate reductase, MTR—methionine synthase, MTRR—methionine synthase reductase, 
TYMS—thymidylate synthase, DHF—dihydrofolate, dTMP—deoxythimidine monophosphate, dUMP—deoxyuridine 
monophosphate, AICAR—5-aminoimidazole-4-carboxamide ribonucleotide, ATIC—AICAR transformylase, THF—
tetrahydrofolate, FAICAR—5-formamidoimidazole-4-carboxamide ribotide, ITP—inosine triphosphate, IMP—inosine 
monophosphate, AMP—adenosine monophosphate, AS—adenylosuccinate, AMPD1—AMP deaminase, ITPA—inosine 
triphosphatase, ADA—adenosine deaminase.
An Interdisciplinary Approach to Psoriasis188
Cells are protected from toxic effects of MTX by transmembrane transporters ABC ( ATP-binding 
cassette), especially ABCB1, ABCC2 and ABCG2. They are ATP dependent, and they actively 
pump MTX out of the cell. On the other hand, solute carriers (SLC), such as SLC19A1 and 
SLCO1B1, facilitate MTX transport in the direction of the concentration  gradient (Figure 1) [19].
Most of the genes coding for the enzymes in folate and adenosine pathway as well as for folate 
and MTX transporters are polymorphic. As genetic polymorphisms may lead to  differences 
in expression and activity of enzymes, polymorphisms in the genes coding for the above 
 mentioned proteins (transporters and enzymes) contribute to interindividual variability 
in therapeutic response and toxicity profile of drugs among patients. Several of the above 
mentioned polymorphic genes were already studied in relation to MTX treatment response 
in rheumatoid arthritis (RA) and cancer, but studies regarding psoriasis are scarce. Studies 
pointing out positive associations between polymorphisms and response to MTX in psoriasis 
and PsA are listed in Table 1.
Genes Variants p-value Predicted effect Reference
Efficacy
TYMS rs34743033 28-bp 
repeat
0.048 Carriers of the 3R allele 
susceptible to poor response 
to MTX
[20]
ABCC1 rs35592 
c.1219-176T>C
0.008 Homozygotes for the major 
allele respond better to MTX
[25]
rs2238476 
c.3391-1960G>A
0.02
rs28364006 
c.4009A>G
0.02
ABCG2 rs13120400 
c.1194+928A>G
0.03 Minor allele associated with 
better response to MTX
[25]
rs17731538 
c.204-1592C>T
0.007 Major allele associated with 
better response to MTX
DHFR rs1232027 
g.80619201G>A
0.02 Minor allele associated with 
better response to MTX
[15]
Toxicity
SLC19A1 rs1051266 c.80A>G 0.025 A allele associated with 
occurrence of adverse 
events
[20]
0.03 A allele associated with 
toxicity
[25]
MTHFR rs1801131 c.1298A>C 
Glu429Ala
0.042 C allele associated with 
lower risk of hepatotoxicity
[20]
rs1801133 c.677C>T 
Ala222Val
0.04 Homozygotes for the minor 
allele more susceptible to 
liver toxicity
[15]
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2.1.1. Genetic variability in folate pathway and MTX treatment
The direct target of MTX within folate pathway is DHFR that converts dihydrofolic acid into 
tetrahydrofolic acid (Figure 1). It is therefore surprising that the impact of DHFR polymor-
phisms on the efficacy and toxicity of treatment of cutaneous psoriasis have not been studied 
Genes Variants p-value Predicted effect Reference
TYMS rs34489327 
nt.1494del6
0.015 Polymorphism increases the 
risk for hepatotoxicity
[20]
rs34743033 28-bp 
repeat
0.0025 3R allele increased risk 
for adverse events in 
patients without folic acid 
supplementation
ATIC rs2372536 c.347C>G 0.038 G allele associated with 
increased risk for MTX 
discontinuation due to 
adverse events
[20]
0.01 Homozygotes for the major 
allele more susceptible to 
MTX toxicity
[22]
rs4672768 
c.1660-135G>A
0.02 Homozygotes for the major 
allele more susceptible to 
MTX toxicity
[22]
ABCC1 rs2238476 
c.3391-1960G>A
0.01 Homozygotes for the major 
allele more susceptible to 
toxicity
[25]
rs3784864 
c.616-1641G>A
0.03 Carriers of at least 
one major allele more 
susceptible to toxicity
rs246240 
c.616-7942A>G
0.0006 Homozygotes for the major 
allele more susceptible to 
toxicity
rs3784862 
c.615+413G>A
0.002 Homozygotes for the major 
allele more susceptible to 
toxicity
rs1967120 
c.489+409G>A
0.01 Carriers of at least 
one major allele more 
susceptible to toxicity
rs11075291 
c.49-3198G>A
0.008 Carriers of at least 
one major allele more 
susceptible to toxicity
ADORA2A rs5760410 
g.24815406G>A
0.03 Homozygotes for the major 
allele more susceptible to 
toxicity
[25]
Table 1. Genetic polymorphisms in folate and adenosine pathway and MTX transporters associated with MTX treatment 
outcome in patients with psoriasis or psoriatic arthritis.
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yet. However, a study that included 281 patients with PsA showed association between the 
minor allele of the rs1232027 polymorphism (35289G>A) and MTX efficacy (p = 0.02; OR = 2.99). 
Patients with rs1232027 A allele had a statistically significant better response to MTX [15].
TYMS is one of the key enzymes providing deoxythymidylate for DNA synthesis, thus 
enabling cell proliferation. Two common functional polymorphisms in TYMS gene could 
influence therapeutic response to MTX [20]. rs34743033 polymorphism in the promoter region 
(5′UTR) is due to a double or triple tandem 28 bp repeat (2R and 3R). Because the 3R allele 
is associated with increased transcription/translation of the gene, rs34743033 may contribute 
to elevated activity of the enzyme and lead to depletion of the substrate for homocysteine 
 methylation (Figure 1). The second most studied TYMS polymorphism, rs34489327, is due to 
a 6 bp deletion at nucleotide 1494 in the 3′UTR (3′UTR 6bp del) and leads to decreased TYMS 
formation [21]. The presence of 3R allele (homozygous or heterozygous variant  genotype) was 
significantly related to poor response to treatment (OR = 2.96; p = 0.048), in fact carriers of 3R 
allele were three times less likely to respond to MTX. Furthermore, among psoriasis patients, 
the 3R allele was significantly (p = 0.029) more frequent in non-responders (64%) compared 
to responders (50%). On the other hand, 3′UTR 6bp del allele did not show any association 
with MTX efficacy. After including only patients not receiving folic acid supplementation, 
both 5′UTR 3R and 3′UTR 6bp del alleles were more frequent in non-responders compared 
to responders, but association with treatment response was not significant [20]. The TYMS 
3′UTR 6bp del polymorphism showed significant association with occurrence of adverse 
events (p = 0.025), irrespective of folic acid supplementation. When researchers excluded 
patients who received folic acid supplementation, both polymorphisms (2R/3R repeat and 
6 bp deletion) appeared to influence adverse events occurrence. Patients with TYMS 5′UTR 
3R/3R genotype had 13-fold (OR = 13.2) higher chance of experiencing any adverse event, 
15-fold (OR = 15.75) higher chance of developing hepatotoxicity and 12-fold (OR = 11.8) 
higher chance of experiencing a symptomatic adverse event compared to patients with other 
genotypes. TYMS 5′-UTR 3R allele also conferred risk for MTX discontinuation (p = 0.033) in 
this group of patients. The 3′UTR 6bp del was more frequent in patients experiencing adverse 
events or symptomatic adverse events, which may be due to the reduced mRNA expression 
caused by this polymorphism. Among patients with no concomitant folate supplementation, 
carriers of 3’UTR 6bp del polymorphism had an eight-fold (OR = 8.4) increased risk of devel-
oping elevated ALT levels [20]. Folic acid supplementation during MTX treatment is thus 
important for decreasing the risk of adverse events.
MTHFR is the central enzyme in folate pathway as it is responsible for the conversion of 
5,10-methylentetrahydrofolate, which is a substrate for TYMS, to 5- methyltetrahydrofolate, 
which is a substrate for homocysteine remethylation (Figure 1). The most studied 
 polymorphisms in MTHFR gene are rs1801133 (c.677C>T, p.Ala222Val) and rs1801131 
(c.1298A>C, p.Glu429Ala), which cause reduced activity of the enzyme. Homozygous (TT) or 
heterozygous (CT) genotypes of the MTHFR 677C>T decrease the enzyme’s  activity by 70 or 
40%, respectively. Furthermore, a homozygous (CC) genotype of the 1298A>C  polymorphism 
decreases the enzyme’s activity for 40%. Due to decreased enzyme activity, patients  hetero- 
zygous for these polymorphisms could be more susceptible to MTX-induced adverse events 
[21]. In the first pharmacogenetic study of psoriasis patients that included 203 patients 
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 followed for 3 months after the initiation of treatment, 104 patients experienced at least one 
adverse event and, out of those, 67 patients (33%) had to discontinue the therapy. The most 
common adverse event was nausea (35%), closely followed by abnormal transaminase levels 
(30%). This study reported lower risk of developing hepatotoxicity in patients with 1298C 
allele (p = 0.042) and in patients with double heterozygosity 677CT/1298AC not receiving folic 
acid supplementation [20]. On the other hand, the frequency of MTHFR polymorphisms did 
not differ significantly between responders and non-responders [20]. Similarly, no associa-
tion was found between MTHFR 677T allele and MTX efficacy in another study that included 
330 patients, of which 250 were classified as responders and 80 as non-responders [22]. PsA 
patients carriers of MTHFR 677TT genotype suffered higher risk for hepatic adverse events 
compared to non-carriers (OR = 2.53; p = 0.04) [15].
Polymorphisms in MTHFD1, MTR and MTRR genes were not studied in psoriasis patients 
yet, although they were associated with MTX toxicity in RA patients in some of the studies 
[19, 23].
2.1.2. Genetic variability in adenosine pathway and MTX treatment
MTX directly inhibits ATIC, the key enzyme in the adenosine pathway (Figure 1). The 
 consequent accumulation of AICAR indirectly leads to accumulation of  adenosine in  circulation, 
which acts as an anti-inflammatory factor. The most studied genetic  polymorphism in ATIC 
is rs2372536 (c.347C>G, p.Thr116Ser), which changes the codon, so serine is incorporated into 
the protein instead of threonine. According to various studies, this polymorphism does not 
affect patient’s response to MTX, and its frequency does not differ between  responders and 
non-responders, but it did have a slight influence on the occurrence of adverse events, espe-
cially nausea, elevated alanine and aminotransferase levels. Patients who discontinued the 
MTX therapy had a higher frequency of the 347G allele (p = 0.038), but genotype distribu-
tion was not significantly different. Carriers of ATIC 347G allele had 1.6-fold increased risk 
of discontinuing the treatment because of adverse events [10, 20]. A study by Warren et al. 
investigated several ATIC polymorphisms and also found association with the outcome of 
MTX therapy. Two polymorphisms, in particular, rs2372536 and rs4672768, were associated 
with MTX toxicity (p = 0.01 and p = 0.02, respectively) [22].
ADA is the enzyme inhibited because of accumulation of AICAR following MTX treatment. 
A functional polymorphism ADA rs73598374 (c.22G>A, p.Asp8Asn) lowers the enzyme 
 activity and may be thus associated with higher efficacy of MTX. The association between this 
 polymorphism and toxicity and efficacy of MTX was, however, not confirmed in psoriasis 
patients [20].
No other polymorphic genes in adenosine metabolic pathway were investigated in  psoriasis 
patients. However, in Slovenian patients with RA, several other genes in adenosine  pathway 
were studied. AMPD1 rs17602729 (c.34C>T, p.Gln45Ter) polymorphism was associated 
with better response to MTX. On the contrary, ITPA rs1127354 polymorphism (c.94C>A, 
p.Pro23Thr) that may decrease the release of adenosine into the circulation was associated 
with poor response to MTX [24].
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The anti-inflammatory effect of adenosine is directly related to its binding to the adenosine 
receptors (ADORA). Only one pharmacogenetic study investigated adenosine receptors so 
far and included 374 patients with chronic plaque psoriasis, who had been treated with MTX 
for at least 3 months. No significant association was detected between polymorphisms in 
ADORA1 gene for adenosine receptor A1 and ADORA2A gene for adenosine receptor A2a 
and the efficacy of MTX. However, there was one polymorphism, ADORA2A rs5760410, that 
was associated with higher probability of adverse events (p = 0.03) [25].
2.1.3. Genetic variability in folate and MTX transport and MTX treatment
Polymorphisms in transporters may influence intracellular MTX levels and, thus, also  influence 
therapeutic effect. SLC19A1 (RFC1) is a reduced folate carrier, which facilitates the MTX transport 
into the cell. Many studies investigated the most common functional  polymorphism in SLC19A1 
(RFC1) gene, rs1051266 (c.80G>A, p.His27Arg) and its influence on MTX treatment outcome. 
According to some studies, this polymorphism influences  toxicity but has no effect on efficacy 
[20, 25]. On the contrary, studies in RA patients showed a better response to MTX in carriers of 
80AA genotype [21]. Psoriasis patients with documented adverse events had a higher frequency 
of 80A allele (p = 0.025) in either homozygous or heterozygous state, so the effect was dominant 
(p = 0.049). When specific adverse events were analysed, SLC19A1 (RFC1) 80A allele was associ-
ated with higher risk for hepatotoxicity (p = 0.053) and symptomatic side effects (p = 0.043). Also, 
an epistatic effect of the loci, RFC1 and TYMS, was observed. Two-loci genotype RFC1 80A/TS 
3′-UTR 6bp del increased the risk of symptomatic side effects nearly three-fold (OR = 2.86). In 
addition, two-loci genotype RFC1 80A/ATIC 347G increased the risk for MTX discontinuation 
(p = 0.0076). Even the RFC 80A allele alone increased the risk of  discontinuation in patients not 
receiving folic acid  supplementation [20]. A weak  association of this polymorphism to the onset 
of toxicity (p = 0.03) was shown in the study by Warren et al.  [25]. However, in PsA, rs1051266 
polymorphism was related neither to efficacy nor to toxicity of MTX [15].
On the other hand, polymorphisms in genes coding for the efflux ABC transporters showed 
association with efficacy as well as toxicity. In the study by Warren et al., two polymorphic 
transporter genes were investigated in psoriasis patients: ABCC1 and ABCG2. In ABCC1, 
40 polymorphisms were tested and three of them were associated with MTX efficacy. The most 
significant one was rs35592 (p = 0.008), the other two were rs2238476 (p = 0.02) and rs28364006 
(p = 0.02). For all the three polymorphisms, the homozygosity for wild-type (major) allele was 
associated with better response to MTX. They also tested 12 ABCG2 SNPs and two of them, 
rs17731538 and rs13120400, were associated with response to MTX although the effect was very 
small. In the case of rs17731538, the wild-type (major) allele was associated with better response 
(p = 0.007; OR = 2.1), whereas in the case of rs13120400 the minor allele was associated with bet-
ter response (p = 0.03; OR = 1.8) [25]. When investigating the influence on toxicity, six ABCC1 
SNPs were found to be associated with MTX adverse events. The strongest correlation was 
found with polymorphisms rs246240 (p = 0.001; OR = 2.2) and rs3784862 (p = 0.002; OR = 2.1), 
in both cases homozygotes for the major allele were at increased risk for toxicity. Carriers of 
these polymorphisms had up to two-fold higher risk of experiencing an adverse drug reaction, 
irrespective of the type of the adverse event. Furthermore, the  correlation between the onset of 
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toxicity and rs2238476 was also observed. Carriers of two copies of the rs2238476 major allele 
had a higher chance of experiencing adverse events (p = 0.01; OR = 2.49). On the other hand, the 
investigated polymorphisms in ABCG2 gene were not associated with  toxicity [25].
2.2. Cyclosporine
Cyclosporine is an orally administered systemic immunosuppressive drug that may be used to 
treat the most resistant forms of psoriasis, especially the plaque-type diseases [9]. It inhibits the 
first phase of T-lymphocyte activation, thus decreasing the levels of inflammatory cytokines, 
among them interleukin-2 (IL2) and interferon- gamma (IFNG) [26]. It is usually administered 
in doses of 2.5–5 mg/kg of body weight/day [9]. The current knowledge on cyclosporine phar-
macogenetics comes from studies in recipients of solid organ transplants. Bioavailability and 
clearance of the drug are influenced by polymorphic P-glycoprotein (ABCB1) in gastrointes-
tinal tract and CYP3A4 and CYP3A5 in the liver, suggesting that these polymorphisms could 
also influence the response to cyclosporine treatment in psoriatic patients [27, 28]. There was 
only one pharmacogenetic study performed on psoriasis patients treated with cyclosporine, 
and it focused only on ABCB1 polymorphisms (Table 2). In this study, rs1045642 (3435C>T) 
was associated with response to cyclosporine (OR = 2.995; p = 0.0075). The frequency of the 
minor T allele was found to be higher in the non-responders group, which means that T allele 
carriers have lower chance of good response [29].
2.3. Acitretin
Acitretin is a vitamin A derivative that belongs to the second-generation retinoids [30]. It reduces 
proliferation of epidermal keratinocytes and promotes their differentiation. It is also used as an 
anti-inflammatory agent. It is administered orally in doses of 0.5–0.8 mg/kg daily. Usually, it is used 
in combination with topical treatment as well as phototherapy [9]. Studies pointing out positive 
associations between polymorphisms and response to acitretin in  psoriasis are listed in Table 3. 
The most widely studied polymorphisms lie in the gene coding for vascular epidermal growth fac-
tor (VEGF). Angiogenesis, especially  inappropriate  vascular expansion, is indeed a common patho-
genic component of psoriasis. Two  polymorphisms within VEGF, rs2010963 and rs833061, have 
been implicated in diseases with strong  angiogenic background [31]. Beside the influence on treat-
ment response, they may also influence the time of onset of the disease [32, 33]. rs833061 was associ-
ated with response to treatment in patients with early onset chronic plaque psoriasis. The frequency 
of rs833061TT genotype was higher in patients who were non-responsive to acitretin compared to 
Genes Variants p-value Predicted effect Reference
Efficacy
ABCB1 rs1045642 c.3435C>T 
p.Ile1145=
0.0075 Minor T allele 
associated with 
poor response to 
cyclosporine
[29]
Table 2. Genetic polymorphism associated with response to cyclosporine treatment in patients with psoriasis.
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good responders (p = 0.04). Patients with the TT genotype were almost twice as likely to not respond 
to therapy as to respond. On the other hand, rs833061 TC genotype frequency was increased in the 
group of patients that responded well to acitretin compared to non-responders (p = 0.01). Patients 
with TC genotype were almost twice as likely to respond to therapy as to fail [31]. However, no 
association was found between rs2010963 and therapeutic response [31].
Another study performed on a group of Italian patients found an association between the 
HLA-G genotype and response to acitretin. HLA-G 14 bp del allele (p = 0.008; OR = 7.74) 
and del/del genotype (p = 0.05) were more frequent in responders compared to non- 
responders [34]. Another pharmacogenetic study investigated polymorphisms in the gene 
coding for  apolipoprotein E (APOE). No association with treatment response was found for 
 polymorphisms APOE rs429358 and rs7412 [35].
2.4. Biologic drugs
Biologic drugs specifically bind to their target, usually inflammation mediators or their recep-
tors, and inhibit their action, which results in anti-inflammatory effect. Biologics used in treat-
ment of psoriasis mainly inhibit tumour necrosis factor alpha (TNFα) and several interleukins 
(IL)—IL17, IL12 and IL23. Among the biologics used for psoriasis treatment, infliximab, 
adalimumab, etanercept are TNFα inhibitors, while ustekinumab is an IL12/23 inhibitor and 
secukinumab is IL17 inhibitor [36, 37].
Biologic drugs are relatively safe and well tolerated. Adverse events occur only in  appro- 
ximately 15% of patients, but the symptoms are usually not severe and are not the reason 
for discontinuation [38]. The most common adverse events are injection-site reaction (pain, 
erythema, itching and haemorrhage) and different infections, mostly of upper respiratory 
tract [9]. However, according to a study performed by Levin et al., 48% of patients discontinue 
treatment due to reasons not related to toxicity [8].
Genes Variants p-value Predicted effect Reference
Efficacy
VEGF rs833061 c.-958C>T 0.04 TT genotype increased 
the risk of poor response 
to acitretin
[31]
0.01 TC genotype increased 
the chance of favourable 
response to acitretin
HLA-G 14 bp DEL 0.008 DEL allele associated 
with better response to 
acitretin
[34]
0.05 DEL/DEL genotype is 
associated with better 
response to acitretin
Table 3. Genetic polymorphisms associated with response to acitretin treatment in patients with psoriasis.
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A study conducted in 2015 that included 4309 patients treated with different biologics 
for 12 months showed that patients experienced dose escalations and discontinuations, 
restarting the same biologic or switching to a different one. Approximately one-third of 
patients had their doses increased until month 6 and 39% until month 12 of treatment. 
On the other hand, half of these patients also discontinued the biologic drug or reduced 
the dose [6]. This indicates that many patients do not achieve sufficient response or lose 
an initially favourable response over time. Pharmacogenetic studies have investigated 
several polymorphisms in genes coding for the targets of biologic drugs and their signal-
ling pathways regarding their contribution to interpatient and intrapatient variability in 
treatment response to biologics in patients with RA, PsA, Chron’s disease and spondylo-
arthritis (SA). However, such studies have been rarely performed exclusively in psoriasis 
patients [39].
2.4.1. Pharmacogenetics of anti-TNFα treatment
The most widely used biologic drugs for systemic psoriasis treatment are TNFα  blockers. 
It is therefore not surprising that the majority of pharmacogenetic studies focused on 
 polymorphisms in the gene coding for TNFα (TNF). TNFα levels are increased in affected 
skin and serum of patients and correlate well with disease severity measured with PASI score. 
TNFα inhibition can reduce the symptoms of the disease [40]. Studies pointing out positive 
associations between polymorphisms and response to anti-TNFα therapy in psoriasis and 
PsA are listed in Table 4.
Genes Variants p-value Predicted effect Reference
Efficacy
TNFα rs1799724 c.-857C>T 0.002 C allele associated with better response 
to etanercept
[49]
0.004 Patients with CT/TT genotypes showed 
greater improvements in PASI score
[47]
rs361525 c.-238A>G 0.049 Patients with GG genotype achieved 
PASI75 more frequently after 6 months 
of anti-TNFα therapy
[47]
0.03 G allele associated with better response 
to etanercept
[48]
rs1799964 c.-1031T>C 0.041 Patients with TT genotype 
demonstrated superior improvements 
in PASI after 6 months of therapy
[47]
rs80267959 
c.186+123G>A
0.0136 G allele favours better response to 
etanercept in PsA patients
[63]
rs1800629 c.-308G>A 0.001 GG genotype associated with better 
response to etanercept
[48]
TNFRSF1B rs1061622 c.676T>G 
p.Met196Arg
0.001 T allele associated with better response 
to etanercept
[49]
0.05 G allele associated with poor response [52]
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Genes Variants p-value Predicted effect Reference
TNFAIP3 rs610604 c.987-152G>T 0.05 G allele associated with better response 
to anti-TNFα therapy
[53]
0.007 T allele associated with better response 
to etanercept
[54]
TRAILR1 rs20575 c.626G>C 
p.Arg209Thr
0.048 CC genotype associated with better 
response to infliximab in PsA
[66]
TNFR1A rs767455 c.36A>G 
p.Pro12=
0.04 AA genotype associated with better 
response to infliximab in PsA
IL23R rs11209026 c.1142G>A 
p.Arg381Gln
0.006 Patients with GG genotype achieved 
more frequently PASI 90 at 6 months
[47]
IL6 rs1800795 c.-237C>G <0.05 Carriers of t C allele respond better to 
therapy
[55]
IL-17F rs763780 c.482T>C 
p.His161Arg
0.0044 TC genotype associated with no 
response to adalimumab at 6 months
[56]
0.023 TC genotype associated with better 
response to infliximab at 3 months
0.020 TC genotype associated with better 
response to infliximab at 6 months
IL17RA rs4819554 c.-947G>A 0.03 AA genotype associated with better 
response at12 weeks
[67]
HLA-C rs10484554 
g.2609009C>T
0.007 C allele associated with better response 
to adalimumab
[54]
TRAF3IP2 rs13190932 c.220C>T 
p.Arg74Trp
0.041 G allele associated with better response 
to infliximab
HLA-A rs9260313 g.1428637T>C 0.05 TT genotype associated with better 
response to adalimumab
FCGR2A rs1801274 c.497A>G 
p.His131Arg
0.03 Patients homozygous for high-affinity 
allele had a higher chance of achieving 
PASI75 after 3 months of therapy
[57]
0.034 PsA patients with high-affinity genotype 
respond better to anti-TNFα drugs 
(etanercept) after 6 months of therapy
[64]
FCGR3A rs396991 c.841T>C 
p.Val158Phe
0.02 Patients homozygous for high-affinity 
allele had a higher chance of achieving 
PASI75 after 3 months of therapy
[57]
0.018 T allele associated with better response 
to etanercept
[58]
PDE3A-
SLCO1C1
rs3794271 
c.50+1078G>A
0.0031 AA genotype associated with better 
response to etanercept
[59]
0.00034 A gender-specific (males) association 
between G allele and poor response 
found in PsA patients
[65]
CD84 rs6427528 c.*1738A>G 0.025 GA genotype associated with better 
response to etanercept
[60]
Pharmacogenetics of Psoriasis Treatment
http://dx.doi.org/10.5772/intechopen.68185
197
The most frequently investigated candidate gene is TNF and rs1800629 (c.-308G>A) within it. 
The polymorphism, which is located in the promoter region of TNF gene, gained  attention 
because it was associated with TNFα secretion and circulating levels [21]. Many studies 
have reported the association of this polymorphism with different traits, such as increased 
 susceptibility to psoriasis and PsA, earlier onset of the disease or poor prognosis of the 
Genes Variants p-value Predicted effect Reference
SPEN rs6701290 
c.84-10630G>A
 <0.05 Associated with anti-TNFα drug 
response in a GWAS
[62]
JAG2 rs3784240 c.475+782C>T
MACC1 rs2390256 c.*2687G>A
GUCY1B3 rs2219538 
c.77+2269G>A
PDE6A rs10515637 
c.2507-1067T>C
CDH23 rs10823825 
c.2290-538T>C
SHOC2 rs1927159 
c.704-13438A>C
LOC728724 rs7820834 
g.129238197T>C
ADRA2A rs553668 
c.450+33966C>T
KCNIP1 rs4867965 
c.88+96839A>C
Toxicity
IL23R rs11209026 c.1142G>A 
p.Arg381Gln
0.005 AG genotype associated with 
development of paradoxical 
psoriasiform reactions
[61]
FBXL19 rs10782001 
c.1361+720G>A
0.028 GG genotype associated with 
development of paradoxical 
psoriasiform reactions
CTLA4 rs3087243 c.*1421G>A 0.012 AG/GG genotype associated 
with development of paradoxical 
psoriasiform reactions
SLC12A8 rs651630 c.1706-272C>T 0.011 TT genotype associated with 
development of paradoxical 
psoriasiform reactions
TAP1 rs1800453 c.1307A>G 0.018 AG genotype associated with 
development of paradoxical 
psoriasiform reactions
Table 4. Genetic polymorphisms associated with response to anti-TNFα therapy in patients with psoriasis or psoriatic 
arthritis.
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 disease [41]. Zhu et al. performed a meta-analysis of 26 studies, which included 2159 pso-
riasis patients, 2360 patients with PsA and more than 2000 controls. They evaluated three 
SNPs in promoter region of TNFα, rs1800629 (c.-308G>A), rs361525 (c.-238A>G) and rs1799724 
(c.-857T>C). They confirmed a protective influence of the polymorphic allele c.-308A. The 
polymorphic alleles of the other two frequently investigated polymorphisms also showed 
association with increased risk for psoriasis and PsA [42]. Another meta-analysis included 
nine studies with a total of 692 patients with RA. The main objective was to determine the 
influence of the TNF c.-308A allele on the response to TNFα inhibitors. The frequency of the 
TNF c.-308A allele was 22% in responders and 37% in patients not responding to treatment, 
irrespective of the choice of the TNFα inhibitor, which indicates that presence of c.-308A 
was associated with a poor response to the drug (p = 0.000245) [43]. This observation was in 
agreement with the  findings of Mugnier et al. that showed better response to infliximab in 
RA patients with c.-308 GG genotype as compared to the patients with c.-308 AA/AG geno-
type [44]. Moreover, Guis et al. observed that RA patients homozygous for c.-308 G allele 
respond better to etanercept than heterozygous patients [45]. Seitz et al. evaluated response 
of RA, PsA and SA patients to infliximab, adalimumab and etanercept and came to the same 
conclusion as the above mentioned studies [46].
Other TNF promoter polymorphisms besides rs1800629 (c.-308G>A) were also investigated, 
among them were rs361525 (c.-238A>G), rs1799724 (c.-857T>C) and rs1799964 (c.-1031T>C). 
Better improvement in PASI score after 6 months of treatment with anti-TNFα drugs was 
achieved in psoriasis patients with TNF -238GG, -857CT/TT and -1031TT genotypes [47]. 
SNPs in TNF promoter were evaluated also by De Simone et al., and rs361525 (-238G allele; 
p = 0.03) and rs1800629 (-308GG genotype; p = 0.001) were found to be associated with good 
drug response [48].
Researchers expanded their interests also to polymorphisms in other genes in TNFα pathways. 
A study performed on 80 Greek patients with psoriasis investigated polymorphisms in TNF 
(c.-238G>A, c.-308G>A and c.-857C>T), tumour necrosis factor receptor superfamily 1A gene 
(TNFRSF1A rs7674559, c.36A>G) and tumour necrosis factor receptor superfamily 1B gene 
(TNFRSF1B rs1061622, c.676T>G). In total, 63 patients were responders and 17 non-responders. 
Carriers of TNF -857C (p = 0.002) and/or TNFRSF1B 676T (p = 0.001) alleles responded signifi-
cantly better to etanercept treatment than non-carriers, while no SNPs were associated with 
response to infliximab or adalimumab [49]. Ongaro et al. reported poorer response to anti-TNFα 
therapy in RA patients with TNFRSF1 676TG genotype as compared to patients with 676TT 
genotype [50]. Recently, a meta-analysis investigated TNFRSF1B (rs1061622) and TNFRSF1A 
(rs7674559) polymorphisms in psoriasis patients. The investigated TNFRSF1A polymorphism 
showed no association with treatment response, but TNFRSF1B 676T allele was associated with 
better response [51]. Another recent study published in 2015 included 518 psoriasis patients 
and 480 healthy controls, but only 90 patients were treated with biologic drugs. In agreement 
with previous studies, they also observed higher frequency of TNFRSF1B 676G allele in non-
responders, and rs1061622 polymorphism was shown to be associated with higher risk for the 
disease and poor response to anti-TNFα and anti-IL12/23 drugs [52].
Polymorphisms within gene coding for tumour necrosis factor alpha-induced protein 3 
(TNFAIP3) were also associated with the response to biologics. A cohort of 433 patients with 
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psoriasis and PsA was tested for two TNFAIP3 SNPs, rs2230926 and rs610604. The results 
showed that rs610604G allele was associated with better response to etanercept, infliximab 
and adalimumab, when patients treated with all these drugs were analysed together (p = 0.05; 
OR = 1.50), but only to etanercept, when each drug treatment was analysed separately 
(p = 0.016; OR = 1.64). In addition, rs2230926 T allele and rs610604 G allele were also predic-
tors of a better outcome. Unfortunately, researchers were unable to reproduce these results in 
a smaller cohort [53].
Furthermore, polymorphisms in genes encoding several interleukins and their receptors were 
investigated in psoriasis patients treated with anti-TNFα drugs. A study that included 109 
psoriasis patients investigated polymorphisms in IL12B (rs6887695 and rs3212227) and IL23R 
(rs7530511 and rs11209026). Carriers of the rs11209026 GG genotype showed better response 
at 6 months of anti-TNFα treatment compared to non-carriers. This study also showed the 
association of HLA-Cw6 haplotype with worse outcome [47]. Another association with HLA 
loci was observed by Masouri et al. who reported the association of HLA-C rs10484554 poly-
morphism with good response to adalimumab (CC or CT genotype, p = 0.007). In the same 
study, also TRAF3IP2 rs13190932, TNFAIP3 rs610604 and HLA-A rs9260313 were associated 
with good response to infliximab, etanercept and adalimumab, respectively [54]. In another 
small study of 60 psoriasis patients, a polymorphism in the IL6 promoter (rs1800795) was 
investigated. Homozygotes and heterozygotes for IL6 rs1800795 C allele responded better 
to therapy [55]. IL-17F rs763780 was also investigated for the association with treatment out-
come. This SNP was associated with no response to adalimumab after 6 months (TC genotype, 
p = 0.0044) and with better response to infliximab after 3 and 6 months (TC genotype; p = 0.023 
and p = 0.020, respectively) [56]. IL17RA rs4819554 polymorphism was associated with better 
response after 12 weeks in carriers of AA genotype compared to AG and GG carriers (p = 0.03).
Genes for Fc gamma receptors were also investigated for their association with response of pso-
riasis patients to anti-TNFα drugs. Patients homozygous for high-affinity alleles of two variants 
FCGR2A-H131R (rs1801274) and FCGR3A-V158F (rs396991) had a higher chance of achieving 
PASI75 after 3 months of therapy [57]. FCGR3A rs396991 was also evaluated by Mendrinou et 
al. who showed that T allele could be a marker of better response to etanercept [58]. Moreover, 
a positive association was found between PDE3A-SLCO1C1 rs3794271AA genotype and PASI 
score in patients treated with etanercept [59]. Association between the CD84 genotypes and 
response to biologics was also evaluated. CD84 rs6427528 polymorphism with its heterozygous 
GA genotype (p = 0.025) was associated with better response to treatment with etanercept [60].
A study performed by Cabaleiro et al. revealed an association between certain polymorphisms 
and occurrence of paradoxical psoriasiform reactions after treatment with anti-TNFα ther-
apy. Polymorphisms in five genes: IL23R rs11209026, FBXL19 rs10782001, CTLA4 rs3087243, 
SLC12A8 rs651630 and TAP1 rs1800453 were associated with the development of this adverse 
reaction to anti-TNFα treatment [61].
Another approach to identify novel loci and SNPs associated with response to anti-TNFα 
drugs included genome-wide association study (GWAS) approach. A small GWAS study was 
recently performed that included 65 psoriasis patients prospectively followed for 12 weeks. 
This study identified 10 SNPs in 10 different genes that could be associated with drug response: 
cadherin-related 23 (CDH2), soc-2 suppressor of clear homolog (SHOC2), adrenoceptor alpha 
An Interdisciplinary Approach to Psoriasis200
2A (ADRA2A), phosphodiesterase 6A (PDE6A), Kv channel interacting protein 1 (KCNIP1), 
spen family transcriptional repressor (SPEN), jagged 2 (JAG2), metastasis  associated in colon 
cancer 1 (MACC1), guanylate cyclase 1, soluble, beta 3 (GUCY1B3) and long intergenic non-
protein coding RNA 977 (LOC728724) gene [62]. However, all these SNPs still await to be 
replicated in independent patient cohorts.
Several studies have also investigated association of genetic polymorphisms with  anti-TNFα 
treatment outcome in PsA cohorts. A study investigating the association of an intronic 
 polymorphism at the position c.+489 of TNF gene (rs80267959) with response to treatment with 
etanercept reported better response in PsA patients carrying G allele compared to  non-carriers 
(p = 0.0136) [63]. Furthermore, PsA patients with high-affinity FCGR2A His/His and His/Arg 
genotypes responded better to anti-TNFα drugs (etanercept) at 6 months of treatment compared 
to patients with low-affinity genotypes (p = 0.034) [64]. A gender-specific association between 
polymorphic rs3794271 G allele and poor response was reported at the PDE3A-SLCO1C1 locus 
(p = 0.00034) [65]. Other candidate genes for prediction of treatment response were suggested, 
including genes coding for death receptors, such as tumour necrosis factor-related apoptosis 
inducing ligand receptor 1 (TRAIL-R1). TRAIL-R1 (rs20575, 626G>C) and TNFR1A (rs767455, 
36A>G) were investigated in a study of 55 PsA patients treated with TNFα blocker infliximab. 
This study concluded that TRAILR1 626CC (p = 0.048) and TNFR1A 36AA (p = 0.04) genotypes 
may be associated with better response after 3 months of infliximab treatment [66].
2.4.2. IL12/23 inhibitors
Ustekinumab is a human monoclonal antibody directed against interleukins IL12 and IL23. 
Studies of polymorphisms affecting patients’ response to these inhibitors are scarce, but 
some of them, listed in Table 5, pointed out positive associations. A cohort of 51 patients 
with  psoriasis treated with ustekinumab was tested for three polymorphisms, including the 
HLA-Cw6 positivity, TNFAIP3 rs610604 polymorphism and LCE3B/3C gene deletions. Better 
and faster response to ustekinumab was observed in HLA-Cw6 positive patients, while no 
significant association with response was observed for the other two investigated genes [68]. 
Another larger study confirmed the role of HLA-Cw6 as Chui et al. reported that HLA-Cw6 
positive patients were more likely to achieve PASI50, 75 and 90 after 28 weeks of treatment 
[69]. On the other hand, Galluzzo et al. suggested that a combination of genetic factors 
 predicts response to ustekinumab better than a single factor. The presence of IL12B rs6887695 
GG genotype in the absence of IL12B rs3212227 AA genotype in HLA Cw6 positive patients 
increased the chance of better treatment outcomes [70].
Another study found association between the TNFRSF1B rs1061622 G allele and poor response 
to anti-IL12/IL23 drugs (p = 0.05) [52]. Furthermore, study in a cohort of 70 psoriasis patients 
treated with ustekinumab reported an association between the IL-17F rs763780 TC genotype 
and no response to ustekinumab after 3 and 6 months of treatment (p = 0.022 and p = 0.016, 
respectively) [56]. IL12B rs3213094 polymorphism was also investigated for association with 
response to ustekinumab and CT genotype was recognized as a predictor of better response 
to the drug (p = 0.017) [60]. In the same study, TNFAIP3 rs610604 GG genotype was associated 
with poor response to ustekinumab (p = 0.031) [60]. Association between two polymorphisms in 
ERAP1gene, rs151823 and rs26653, and good response to ustekinumab was also reported [54].
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3. Future perspectives
Large heterogeneity in patients’ response to therapy calls for new molecular predictors of 
treatment response. We have searched the current literature to compile a comprehensive 
review of today’s knowledge on genetic variants that may influence the outcome of psoriasis 
systemic treatment. A rather small number of studies were performed so far, and, although 
some of the results are encouraging, even larger number of studies shows inconsistent or even 
conflicting results. The investigated patient cohorts were with a few exceptions rather small 
and the number of evaluated polymorphisms limited. The future studies should expand the 
range of polymorphisms investigated by either looking into other pathways besides the ones 
directly involved in drug mechanisms, such as metabolism and transport, though they cer-
tainly are important in treatment response. Great interindividual variability in treatment out-
come among patients could also be associated with heterogeneous pathology. Not all of the 
Genes Variants p-value Predicted effect Reference
Efficacy
IL-17F rs763780 c.482T>C 
p.His161Arg
0.022 TC genotype 
associated with no 
response at 3 months
[56]
0.016 TC genotype 
associated with no 
response at 6 months
IL12B rs3213094 
c.89-432G>A
0.017 CT genotype 
associated with 
favourable response
[60]
TNFAIP3 rs610604 
c.987-152G>T
0.031 GG genotype 
associated with poor 
response
HLA-C Cw6POS/NEG 0.008 Cw6POS patients 
respond better and 
faster
[68]
0.035 Cw6POS patients 
respond better
[69]
TNFRSF1B rs1061622 c.676T>G 
p.Met196Arg
0.05 G allele associated 
with poor response
[52]
ERAP1 rs151823 
c.-454-1169A>C
0.026 CC genotype 
associated with better 
response
[54]
rs26653 c.380G>C 
p.Arg127Pro
0.016 GG genotype 
associated with better 
response
Table 5. Genetic polymorphisms associated with response to ustekinumab in patients with psoriasis.
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patients have the same pathogenesis, although they present with similar symptoms. Genetic 
defects in various pathways could be causative of the disease or support disease occurrence, 
and these defects in so-called susceptibility genes should also be checked regarding their 
influence on treatment outcome. The heterogeneity in pathogenesis could also be the reason 
for inconsistency in pharmacogenetic studies conducted so far. The hypothesis-free approach 
of the GWAS studies could help to overcome these obstacles and help to elucidate genetic 
factors associated with both disease pathways and treatment responses; however, such stud-
ies should include large number of well-characterized patients. Furthermore, the identified 
predictors of the course of the disease and of the treatment response should be validated in 
independent patient samples.
Such validated pharmacogenetic biomarkers would enable us to characterize patients 
with psoriasis by their genetic characteristics and not just their phenotype and would 
allow for a more targeted approach to pharmacotherapy. The patients could be stratified 
according to their genetic defects affecting the molecular mechanisms of the disease in 
combination with genetic defects in pathways of drug metabolism and transport as well as 
in drug targets and effector pathways. Pharmacogenetic factors should also be combined 
with clinical data to find the most suitable way of stratifying patients into groups eligible 
for certain treatment strategies. If a physician would be able to predict patient’s response 
based on pharmacogenetic polymorphisms, problems of inefficacy and toxicity could be 
overcome by choosing the right drug and dose for a particular patient. This would also 
help to lower the cost of the treatment and, what is more important, relieve some of 
the patient’s psychological burden, which is often overlooked in psoriasis. Methods for 
genotyping are fast, reliable, relatively cheap and suitable for use in diagnostic labora-
tories. Despite the costs that would be spent on implementation of new genetic analysis 
methods into everyday clinical practice, pharmacogenetics-based personalized treatment 
approach would probably lower the expenses of psoriasis treatment due to more rational 
pharmacotherapy.
4. Conclusions
Personalized medicine is emerging as the innovative approach also in psoriasis treatment. A 
general belief that every drug can help every patient is getting obsolete. However, to be able 
to properly tailor the patient’s treatment, consistent biomarkers of the treatment  outcome 
must be identified and validated. In psoriasis treatment, the search for such biomarkers is 
still in its beginnings. In this chapter, we summarized the current knowledge on genetic pre-
dictors of response to MTX, cyclosporine, acitretin and biologic drugs. Several studies have 
already identified some of the genetic variants associated with response to a particular drug, 
but none of the genetic polymorphisms within these genes were recognized as specific enough 
to be used in clinical practice so far. However, some promising candidates for predictors of 
treatment response were identified that could be used in personalized treatment of psoriasis 
patients if validated in further studies.
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